BioPharmSignal logoBioPharmSignal

Biotech News

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

MiMedx (MDXG)MiMedxEarnings

MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026.

Related news

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MDXGMiMedx2026-04-22 12:00 EST

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

RXRXRecursion2026-02-18 13:30 EST

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

ADMAADMA Biologics2026-02-18 12:00 EST

ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

CHRSCoherus BioSciences, Inc.2026-03-09 20:15 EST

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

STTKShattuck Labs2026-03-05 11:15 EST

Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

CHRSCoherus BioSciences, Inc.2026-03-02 14:30 EST

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

ADMAADMA Biologics2026-02-25 21:05 EST

ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

RXRXRecursion2026-02-25 11:30 EST

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ENTXEntera Bio2026-08-07 20:05 EST

Entera Announces Second Quarter 2026 Financial Results and Business Updates

View all latest news

MiMedx

Placental Tissue Products MIMEDX develops and commercializes placental-tissue products for wound care, burns and surgery. Its processing and product portfolio are designed to provide extracellular-matrix and biologic materials that support healing and tissue repair. Wound-Care Portfolio The company has more than a decade of experience...

Recent company news

MDXGMiMedx2026-07-29 20:07 EST

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-07-29 20:01 EST

MIMEDX to Acquire Sanara MedTech

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MDXGMiMedx2026-05-21 12:45 EST

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

MDXGMiMedx2026-05-08 12:00 EST

MIMEDX Announces Launch of G4Derm® Plus

Stock data

Close
4.18 USD
Market cap
531.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States